Evaluation of Tacrolimus in Ulcerative Colitis: A Retrospective Analysis of Factors Influencing Remission Induction and Maintenance - Takeaways - MDSpire

Evaluation of Tacrolimus in Ulcerative Colitis: A Retrospective Analysis of Factors Influencing Remission Induction and Maintenance

  • By

  • Ayumi Ito

  • Shun Murasugi

  • Miki Koroku

  • Maria Yonezawa

  • Teppei Omori

  • Shinichi Nakamura

  • Katsutoshi Tokushige

  • Yousuke Nakai

  • March 5, 2026

  • 0 min

Share

  • 1

    Tacrolimus (TAC) is effective for inducing remission in ulcerative colitis (UC), with a remission rate of approximately 50%.

  • 2

    The study evaluated factors influencing remission induction and maintenance in UC patients treated with TAC over a 52-week period.

  • 3

    Maintenance therapy for UC often involves azathioprine (AZA), which can cause serious adverse events, complicating treatment.

  • 4

    The study included 136 UC patients receiving TAC therapy, assessing remission rates and drug-specific outcomes across four phases.

  • 5

    Colorectal resection rates due to UC recurrence after TAC remission induction can be as high as 30% to 40% within 52 weeks.

Original Source(s)

Evaluation of Tacrolimus in Ulcerative Colitis: A Retrospective Analysis of Factors Influencing Remission Induction and Maintenance

  • by Ayumi Ito, Shun Murasugi, Miki Koroku, Maria Yonezawa, Teppei Omori, Shinichi Nakamura, Katsutoshi Tokushige, Yousuke Nakai

  • March 5, 2026

Related Content

Metabolic and Structural Alterations Linked to Mice's Vulnerability to Primary Echinostoma caproni Infections

Strategies for Organ Regeneration Using Cell Therapy

AMA Backs Structured Vaccine Review

Medical societies and public health groups will collaborate on policy questions and evidence briefs for the 2026 to 2027 respiratory virus season.